According to filings with the U.S. Securities and Exchange Commission, Nevakar is raising $12,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Navneet Puri played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Nevakar
Repositioning Drugs for a Better Outcome. Nevakar is a specialty injectable pharmaceutical company, focused on developing innovative products in injectable and ophthalmic space. Our goal is to develop enhanced products that address unmet clinical and/or commercial needs of currently [FDA] approved molecules, through intensive R&D and clinical efforts. Nevakar Injectables, Inc. is a wholly owned subsidiary of Nevakar, Inc., a fully integrated privately held, late-stage biopharmaceutical company with an extensive portfolio of products in the ophthalmic and injectable areas. Nevakar Injectables is developing a broad portfolio of injectable products for use in the hospital and ambulatory care settings. The Company has active programs in critical patient care, acute pain management, long acting injectables, and hospital injectables. 

To learn more about Nevakar, visit http://www.nevakar.com

Contact:
Navneet Puri, Chief Executive Officer
908-367-7400

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.